1156 related articles for article (PubMed ID: 31950545)
1. Comedication prescription patterns and potential for drug-drug interactions with antiretroviral therapy in people living with human immunodeficiency virus type 1 infection in Germany.
Lopes S; O'Day K; Meyer K; Van Stiphout J; Punekar Y; Radford M; Haas JS
Pharmacoepidemiol Drug Saf; 2020 Mar; 29(3):270-278. PubMed ID: 31950545
[TBL] [Abstract][Full Text] [Related]
2. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K;
Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123
[TBL] [Abstract][Full Text] [Related]
3. Antiretroviral therapy among people with HIV with comorbidities in the United States: a retrospective cohort study.
Buysman EK; Kumar P; McNiff K; Goswami S; Paudel M; Prajapati G; Tadese BK
Curr Med Res Opin; 2023 Nov; 39(11):1451-1462. PubMed ID: 37766585
[TBL] [Abstract][Full Text] [Related]
4. Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era.
Ruderman SA; Crane HM; Nance RM; Whitney BM; Harding BN; Mayer KH; Moore RD; Eron JJ; Geng E; Mathews WC; Rodriguez B; Willig AL; Burkholder GA; Lindström S; Wood BR; Collier AC; Vannappagari V; Henegar C; Van Wyk J; Curtis L; Saag MS; Kitahata MM; Delaney JAC
J Acquir Immune Defic Syndr; 2021 Mar; 86(3):339-343. PubMed ID: 33148997
[TBL] [Abstract][Full Text] [Related]
5. Analysis of drug-drug interactions among patients receiving antiretroviral regimens using data from a large open-source prescription database.
Patel N; Borg P; Haubrich R; McNicholl I
Am J Health Syst Pharm; 2018 Aug; 75(15):1132-1139. PubMed ID: 29903710
[TBL] [Abstract][Full Text] [Related]
6. The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV.
Stellbrink HJ; Lazzarin A; Woolley I; Llibre JM
HIV Med; 2020 Mar; 21 Suppl 1():3-16. PubMed ID: 32017355
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of antiretroviral drug regimens and drug-drug interactions between younger and older HIV-infected patients at a tertiary care teaching hospital in South Korea.
Park MS; Yang YM; Kim JS; Choi EJ
Ther Clin Risk Manag; 2018; 14():2229-2241. PubMed ID: 30519031
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial.
Winston A; Post FA; DeJesus E; Podzamczer D; Di Perri G; Estrada V; Raffi F; Ruane P; Peyrani P; Crofoot G; Mallon PWG; Castelli F; Yan M; Cox S; Das M; Cheng A; Rhee MS
Lancet HIV; 2018 Apr; 5(4):e162-e171. PubMed ID: 29475804
[TBL] [Abstract][Full Text] [Related]
9. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
Orrell C; Hagins DP; Belonosova E; Porteiro N; Walmsley S; Falcó V; Man CY; Aylott A; Buchanan AM; Wynne B; Vavro C; Aboud M; Smith KY;
Lancet HIV; 2017 Dec; 4(12):e536-e546. PubMed ID: 28729158
[TBL] [Abstract][Full Text] [Related]
10. Current Antiretroviral Treatment Among People With Human Immunodeficiency Virus in the United States: Findings from the Centers for AIDS Research Network of Integrated Clinic Systems Cohort.
Ma J; Nance RM; Delaney JAC; Whitney BM; Bamford L; Gravett RM; Moore RD; Napravnik S; Mayer KH; Jacobson JM; Christopoulos K; Burkholder GA; Keruly J; Eron JJ; Martin J; Cachay ER; Saag MS; Crane HM; Kitahata MM
Clin Infect Dis; 2022 Sep; 75(4):715-718. PubMed ID: 35134850
[TBL] [Abstract][Full Text] [Related]
11. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
[TBL] [Abstract][Full Text] [Related]
12. Lipid profile changes associated with antiretroviral therapies in a real-world cohort.
Rotea-Salvo S; Giménez-Arufe V; Martínez-Pradeda A; Fernández-Oliveira C; Mena-de-Cea Á; Margusino-Framiñán L; Martín-Herranz I; Cid-Silva P
Farm Hosp; 2023; 47(5):210-217. PubMed ID: 37349200
[TBL] [Abstract][Full Text] [Related]
13. Polypharmacy and potential drug-drug interactions for people with HIV in the UK from the Climate-HIV database.
Okoli C; Schwenk A; Radford M; Myland M; Taylor S; Darley A; Barnes J; Fox A; Grimson F; Reeves I; Munshi S; Croucher A; Boxall N; Benn P; Paice A; van Wyk J; Khoo S
HIV Med; 2020 Sep; 21(8):471-480. PubMed ID: 32671950
[TBL] [Abstract][Full Text] [Related]
14. Retrospective evaluation of an observational cohort by the Central and Eastern Europe Network Group shows a high frequency of potential drug-drug interactions among HIV-positive patients receiving treatment for coronavirus disease 2019 (COVID-19).
Lakatos B; Kowalska J; Antoniak S; Gokengin D; Begovac J; Vassilenko A; Wasilewski P; Fleischhans L; Jilich D; Matulionyte R; Kase K; Papadopoulus A; Rukhadze N; Harxhi A; Hofman S; Dragovic G; Vasyliev M; Verhaz A; Yancheva N; Oprea C;
HIV Med; 2022 Jul; 23(6):693-700. PubMed ID: 34859557
[TBL] [Abstract][Full Text] [Related]
15. Drug interaction after ritonavir discontinuation: considerations for antiretroviral therapy changes in renal transplant recipients.
Jimenez HR; Natali KM; Zahran AAR
Int J STD AIDS; 2019 Jun; 30(7):710-714. PubMed ID: 30961466
[TBL] [Abstract][Full Text] [Related]
16. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
Venter WDF; Moorhouse M; Sokhela S; Fairlie L; Mashabane N; Masenya M; Serenata C; Akpomiemie G; Qavi A; Chandiwana N; Norris S; Chersich M; Clayden P; Abrams E; Arulappan N; Vos A; McCann K; Simmons B; Hill A
N Engl J Med; 2019 Aug; 381(9):803-815. PubMed ID: 31339677
[TBL] [Abstract][Full Text] [Related]
17. No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide/emtricitabine plus raltegravir, dolutegravir or elvitegravir/cobicistat during a two-year follow-up.
Calza L; Borderi M; Colangeli V; Borioni A; Coladonato S; Granozzi B; Viale P
Infect Dis (Lond); 2020 Apr; 52(4):249-256. PubMed ID: 31876437
[No Abstract] [Full Text] [Related]
18. Tenofovir disoproxil fumarate/emtricitabine is associated with a higher risk of hypocalcemia compared to abacavir/lamivudine - results from a German cohort study.
Noe S; Heldwein S; Jaeger H; Page M; Wolf E
Int J STD AIDS; 2019 Apr; 30(5):447-452. PubMed ID: 30630396
[TBL] [Abstract][Full Text] [Related]
19. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials.
Sax PE; Erlandson KM; Lake JE; Mccomsey GA; Orkin C; Esser S; Brown TT; Rockstroh JK; Wei X; Carter CC; Zhong L; Brainard DM; Melbourne K; Das M; Stellbrink HJ; Post FA; Waters L; Koethe JR
Clin Infect Dis; 2020 Sep; 71(6):1379-1389. PubMed ID: 31606734
[TBL] [Abstract][Full Text] [Related]
20. Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries.
Cohen J; Beaubrun A; Bashyal R; Huang A; Li J; Baser O
AIDS Res Ther; 2020 Apr; 17(1):12. PubMed ID: 32238169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
